Europas førende søgning efter kliniske forsøg

Lna043

Lna043 is being studied in a clinical trial for people with symptomatic knee osteoarthritis. The trial looks at whether it can improve knee structure and checks safety and tolerability compared with placebo. It focuses on adults with knee osteoarthritis in a phase 2 study.

Table of contents

Overview of the trial

The clinical trial NCT04864392 studied Lna043 in people with symptomatic knee osteoarthritis.[1] It was an interventional study, which means researchers gave a study treatment and then measured the results.[1]

This was a phase 2 trial, a stage of research that helps researchers learn more about whether a treatment may work and how safe it is.[1] The study was completed.[1]

Who the study is for

The study focused on patients with symptomatic knee osteoarthritis.[1] Symptomatic means the condition is causing symptoms, such as pain or stiffness, but the trial data do not list more detailed entry rules.[1]

The trial looked at the target knee, which is the knee chosen for measurement in the study.[1]

What the study is testing

The study compared Lna043 with placebo.[1] A placebo is a look-alike treatment used for comparison and does not contain the active study treatment.[1]

The brief study summary says the researchers wanted to evaluate knee structural changes from baseline in the central medial tibiofemoral compartment of the target knee at week 104.[1] In simple terms, they wanted to see whether the knee joint looked different after treatment compared with the starting point.[1]

What the study measures

The main outcome was change from baseline in the knee structure.[1] Baseline means the starting point before treatment begins.[1]

The study used the central medial tibiofemoral compartment as the main area for measurement.[1] This is a specific part of the knee joint, and it helps researchers focus on a precise area rather than the whole knee at once.[1]

The planned assessment time was week 104, which is about two years after the start of the study.[1]

Trial status and size

The trial was marked as completed.[1] It enrolled 581 participants.[1] This makes it a fairly large phase 2 study for a joint disease trial.[1]

Trial ID Phase Condition studied Status Enrollment
NCT04864392 Phase 2 Osteoarthritis / symptomatic knee osteoarthritis Completed 581

FAQ

  • What is being studied in the Lna043 trial? The trial is studying whether Lna043 can change knee structure in people with symptomatic knee osteoarthritis. It also checks safety and tolerability.
  • Who can take part in the study? The study is for patients with symptomatic knee osteoarthritis. The trial data do not give more detailed entry rules.
  • What phase is the Lna043 trial? This is a phase 2 trial. Phase 2 studies usually look more closely at whether a treatment may work and how safe it is.
  • What condition is the trial focused on? The trial is focused on osteoarthritis, specifically symptomatic knee osteoarthritis. It looks at the target knee.
  • What outcome is the study measuring? The main outcome is the change from baseline in knee structure. The study checks this in the central medial tibiofemoral compartment at week 104.

Igangværende kliniske forsøg for Lna043

  • Undersøgelse af lægemidlet LNA043 til behandling af slidgigt i knæet

    Rekrutterer ikke

    1 1
    Undersøgte lægemidler:
    Tjekkiet Danmark Estland Polen Spanien

Ordliste

  • Osteoarthritis: A joint disease where the cartilage and other joint parts wear down over time, causing pain and stiffness.
  • Symptomatic: Having clear symptoms, such as pain, swelling, or stiffness.
  • Knee structure: The parts inside and around the knee joint, including bone, cartilage, and joint space.
  • Placebo: A treatment that looks like the study drug but does not contain the active treatment. It is used for comparison.
  • Phase 2: A study stage that helps researchers learn more about whether a treatment may work and how safe it is.
  • Safety: How well a treatment can be used without causing unacceptable harm.
  • Tolerability: How well patients can handle a treatment, including whether side effects are manageable.
  • Interventional study: A study where researchers give a treatment or intervention and then measure the results.
  • Baseline: The starting point before treatment begins. Later results are compared with this point.
  • Central medial tibiofemoral compartment: A specific part of the knee joint that is being measured in the study.
  • Week 104: The time point 104 weeks after the start of the study, which is about 2 years.

Referencer

  1. https://kliniske-forsoeg.dk/forsog/undersogelse-af-laegemidlet-lna043-til-behandling-af-slidgigt-i-knaeet/